Zobrazeno 1 - 10
of 420
pro vyhledávání: '"J, Seckl"'
Autor:
Harika Yumru Celiksoy, Catriona Dickie, Michael J. Seckl, Esra Aydın, Hamdullah Sozen, Samet Topuz, Christina Fotopoulou
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Aim of the present analysis is to compare the impact of antihormonal therapy versus cytotoxic chemotherapy versus a watch a wait approach on disease-free survival (DFS) in the adjuvant setting of patients who underwent complete cytoreductive
Externí odkaz:
https://doaj.org/article/6136ca699e09480c8ce7ee3f021aa220
Autor:
Jean-Yves Blay, Paolo Casali, Isabelle Ray-Coquard, Michael J. Seckl, Jourik Gietema, Wouter W. de Herder, Martyn Caplin, Heinz-Josef Klümpen, Olivier Glehen, Lucjan Wyrwicz, Robin Peeters, Lisa Licitra, Nicolas Girard, Sophie Piperno-Neumann, Ellen Kapiteijn, Ahmed Idbaih, Enrico Franceschi, Annalisa Trama, Anna-Maria Frezza, Peter Hohenberger, Nadia Hindi, Javier Martin-Broto, Johanna Schell, Muriel Rogasik, Stephane Lejeune, Kathy Oliver, Francesco de Lorenzo, Ariane Weinman
Publikováno v:
The Lancet Regional Health. Europe, Vol 39, Iss , Pp 100861- (2024)
Summary: About 500,000 patients with rare adult solid cancers (RASC) are diagnosed yearly in Europe. Delays and unequal quality of management impact negatively their survival. Since 2017, European reference networks (ERN) aim to improve the quality o
Externí odkaz:
https://doaj.org/article/4f20025ebba2481ba272e65734dc8627
Autor:
Yakinthi Chrisochoidou, Rajat Roy, Pooyeh Farahmand, Guadalupe Gonzalez, Jennifer Doig, Lukas Krasny, Ella F. Rimmer, Anne E Willis, Marion MacFarlane, Paul H. Huang, Neil O. Carragher, Alison F. Munro, Daniel J. Murphy, Kirill Veselkov, Michael J. Seckl, Miriam F. Moffatt, William O. C. Cookson, Olivier E. Pardo
Publikováno v:
Cell Death and Disease, Vol 14, Iss 11, Pp 1-20 (2023)
Abstract Mesothelioma is an aggressive cancer of the mesothelial layer associated with an extensive fibrotic response. The latter is in large part mediated by cancer-associated fibroblasts which mediate tumour progression and poor prognosis. However,
Externí odkaz:
https://doaj.org/article/aaf6d7ac3e1a4d1b86de96ee85ac0b92
What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the management of multiple malignancies including lung cancer. However, the optimal use of these agents in terms of duration, dose and administration frequency remains unknown
Externí odkaz:
https://doaj.org/article/a5a62f90e4e941adb3cf3b468bbe74f3
Autor:
R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, M. J. Seckl
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
FGFR-1 upregulation has been associated with endocrine therapy resistance in breast cancer patients. Here the authors report the results of a phase IIa study to assess the safety and efficacy of AZD454, an inhibitor of FGFR-1, 2 and 3 receptor tyrosi
Externí odkaz:
https://doaj.org/article/dd21946084ab4cad9d70fb08c6b96016
Autor:
Geoffrey J. Maher, Rosemary A. Fisher, Baljeet Kaur, Xianne Aguiar, Preetha Aravind, Natashia Cedeno, James Clark, Debbie Damon, Ehsan Ghorani, Adam Januszewski, Foteini Kalofonou, Ravindhi Murphy, Rajat Roy, Naveed Sarwar, Mark R. Openshaw, Michael J. Seckl
Publikováno v:
npj Genomic Medicine, Vol 7, Iss 1, Pp 1-8 (2022)
Abstract Tumours expressing human chorionic gonadotropin (hCG), the majority of which are difficult to biopsy due to their vascularity, have disparate prognoses depending on their origin. As optimal management relies on accurate diagnosis, we aimed t
Externí odkaz:
https://doaj.org/article/4537b0fad97f47fca2fad90941d4c7aa
Autor:
R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, V. Ferguson, M. J. Seckl
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/a49b3f62276b4ad18eb4fc87fff91c8d
Autor:
DING Lai-feng, ZHANG Cong-cong, HU Qing-yu, Olivier E. PARDO, Michael J. SECKL, WANG Yu-lan, WU Jun-fang
Publikováno v:
Chinese Journal of Magnetic Resonance, Vol 36, Iss 04, Pp 534-543 (2019)
Choriocarcinoma (CC) is a malignant trophoblastic tumor that occurs in women of childbearing age. Its cure rate could be over 90% following single drug or multidrug chemotherapy with methotrexate, 5-fluorouracil and etc. Chemoresistance is the main c
Externí odkaz:
https://doaj.org/article/fef24166b25849d0a1ea9e0d984ee7cf
Autor:
Charleen Chan Wah Hak, Christopher Coyle, Arwa Kocache, Dee Short, Naveed Sarwar, Michael J. Seckl, Michael A. Gonzalez
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Etoposide (E) at 100 mg/m2 combined with Cisplatin (P) at 20 mg/m2 represents an induction 2-day regimen embedded in our clinical practice for patients with advanced GCT or TN at high risk of early death. We evaluated 24/7 Em-EP a
Externí odkaz:
https://doaj.org/article/6f9fbebcc51d47eab8aa9e91761b77a1
Autor:
Philip Savage, David Monk, Jose R. Hernandez Mora, Nick van der Westhuizen, Jennifer Rauw, Anna Tinker, Wendy Robinson, Qianqian Song, Michael J. Seckl, Rosemary A. Fisher
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Gestational choriocarcinoma is a rare malignancy believed to arise from the trophoblast cells of the placenta. Despite the frequently aggressive clinical nature, choriocarcinoma has been routinely curable with cytotoxic chemothera
Externí odkaz:
https://doaj.org/article/e9ed2f55274d433cb0846a7a58743447